JAZZ News and Press, Jazz Pharmaceuticals plc From 03/01/22

Jazz Pharmaceuticals plc (JAZZ) Q4 2021 Earnings Conference Call March 1, 2022 4:30 PM ET Company Participants Andrea Flynn - VP & Head, IR Bruce Cozadd - Co-Founder, Chairman & CEO Daniel Swisher - President Robert Iannone - EVP, Research & Development & Chief Medical Officer...

Jazz Pharmaceuticals press release (NASDAQ:JAZZ): Q4 Non-GAAP EPS of $4.21 beats by $0.58. Revenue of $896.73M (+34.7% Y/Y) beats by $30.02M. Shares -1.05%. Growing and durable commercial franchises drove 2021 total revenues of $3.1 billion; 31% increase compared to 2020 Significant deleverag...

JAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2021 FINANCIAL RESULTS PR Newswire DUBLIN , March 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2021 and provid...

Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences Cowen Health Care Conference Needham Virtual Neuroscience Forum PR Newswire DUBLIN , Feb. 28, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the ...

Jazz Pharmaceuticals to Report 2021 Fourth Quarter and Full Year Financial Results on March 1, 2022 PR Newswire DUBLIN , Feb. 15, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 fourth quarter and...

The second part to my series on the Biotechnology industry will be finding the necessary skills to research companies. The concepts are simple, but the information is sometimes difficult to find, and so I provide some examples. The five companies I analyze are just examples, and u...

Jazz Pharmaceuticals laid out its 2025 vision at the J.P. Morgan Healthcare Conference last month. The company expects to generate $5 billion in revenues in 2025 and a five percentage points operating margin improvement. The margin goal seems achievable but there are risks on the ...

Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...

Jazz Pharmaceuticals faces increased competition after a competitor was able to manufacture a generic version of their Narcolepsy drug Xyrem. The market for Narcolepsy, which is Jazz Pharm’s best-performing drug market, has a stable yet extremely slow growth rate. The compa...

Jazz Pharmaceuticals (JAZZ -0.5%) completed the submission of a supplemental biologics license application to the U.S. Food and Drug Administration seeking approval for a Monday/Wednesday/Friday intramuscular dosing schedule for Rylaze for use as a component of a multi-agent chemotherape...